S. Cuffe

发表

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Y. Shentu, A. Tafreshi, M. O'Brien, 2016, The New England journal of medicine.

Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells

S. Gray, S. Finn, S. Cuffe, 2017, Cancers.

Patient preference: a comparison of electronic patient-completed questionnaires with paper among cancer patients.

O. Espin-Garcia, S. Cuffe, S. Alibhai, 2016, European journal of cancer care.

A Pooled Exploratory Analysis of the Effect of Tumor Size and KRAS Mutations on Survival Benefit From Adjuvant Platinum-Based Chemotherapy in Node-Negative Non–Small Cell Lung Cancer

P. Jänne, J. Pignon, L. Seymour, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

A. Tafreshi, J. Riess, M. Pietanza, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)

B. O'neill, B. Hennessy, C. Mariette, 2017, BMC Cancer.

Outcomes for Esophageal Squamous Cell Carcinoma Treated with Curative Intent in a Western Cohort: Should Multimodal Therapy Be the Gold Standard?

J. Reynolds, S. Cuffe, D. O'Toole, 2018, World Journal of Surgery.

Cancer survivors' experience of OptiMal, a 6-week, occupation-based, self-management intervention

K. Bennett, D. Connolly, C. Grant, 2018, British Journal of Occupational Therapy.

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First‐Line Platinum‐Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS‐lung Trial

H. Groen, V. Torri, U. Dafni, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial.

U. Dafni, R. Stahel, S. Peters, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

U. Dafni, R. Stahel, S. Peters, 2017, The Lancet. Respiratory medicine.

Use of iPad technology to determine cancer patient-reported preferences for and understanding of pharmacogenetic testing (PGT).

Geoffrey Liu, Wei Xu, S. Cuffe, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer patients’ acceptability of incorporating an epidemiology questionnaire within a clinical trial

Bingshu E. Chen, W. Parulekar, Z. Kassam, 2015, Clinical trials.

A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial

N. Reinmuth, U. Dafni, R. Stahel, 2020 .

In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC

K. O'Byrne, S. Finn, S. Cuffe, 2016, Oncotarget.

Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis

U. Dafni, R. Stahel, R. Rosell, 2022, ESMO open.

Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study

G. Beretta, E. Van Cutsem, J. Tabernero, 2021, Gastric Cancer.

OA14.01 KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer

A. Tafreshi, M. O'Brien, J. Brahmer, 2019, Journal of Thoracic Oncology.

Altered expression of ACOX2 in non-small cell lung cancer

Pilib Ó Broin, S. Gray, S. Finn, 2022, BMC Pulmonary Medicine.

Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.

Y. Shentu, A. Tafreshi, M. O'Brien, 2017 .

Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC

S. Gray, A. Baird, S. Finn, 2022, Diagnostics.

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.

U. Dafni, R. Stahel, C. Britschgi, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples

A. Fabre, M. Joerger, W. Jochum, 2019, Diagnostics.

Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452).

B. O'neill, M. Lowery, J. Reynolds, 2021 .

ICORG 10-14: Neo-AEGIS: A randomized clinical trial of neoadjuvant and adjuvant chemotherapy (modified MAGIC regimen) versus neoadjuvant chemoradiation (CROSS protocol) in adenocarcinoma of the esophagus and esophagogastric junction.

B. O'neill, J. Reynolds, M. Keane, 2014 .

Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial.

U. Dafni, R. Stahel, S. Peters, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

The role of DNA repair pathways in cisplatin resistant lung cancer.

K. O'Byrne, D. Richard, S. Finn, 2014, Cancer treatment reviews.

Targeting the fibroblast growth factor receptor family in cancer.

K. O'Byrne, S. Finn, S. Cuffe, 2016, Cancer treatment reviews.

Cisplatin and gemcitabine in the management of metastatic penile cancer.

K. O'Byrne, C. Farrelly, D. Power, 2009, Urologic oncology.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kazuhiro Yoshida, A. Benson, Y. Bang, 2018, The Lancet.

Strategic targeting of the PI3K–NFκB axis in cisplatin-resistant NSCLC

K. O'Byrne, K. Umezawa, A. Baird, 2014, Cancer biology & therapy.

Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study.

K. O'Byrne, M. Seckl, S. Cuffe, 2012, Lung cancer.

The emerging role of microRNAs in resistance to lung cancer treatments.

K. O'Byrne, S. Gray, S. Finn, 2015, Cancer treatment reviews.

Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin

K. O'Byrne, S. Gray, S. Finn, 2021, Translational oncology.

Non-coding RNA repertoires in malignant pleural mesothelioma.

S. Gray, S. Finn, S. Cuffe, 2015, Lung cancer.

Lung cancer stem cells: The root of resistance.

K. O'Byrne, S. Gray, S. Finn, 2016, Cancer letters.

Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways.

S. Finn, S. Cuffe, M. Barr, 2016, Pharmacology & therapeutics.

Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome

A. Azad, G. Darling, Geoffrey Liu, 2017, Oncotarget.

MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer

K. O'Byrne, S. Gray, S. Finn, 2021, Translational lung cancer research.

BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC.

K. O'Byrne, S. Gray, S. Finn, 2018, Cancer letters.

Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC

K. O'Byrne, S. Gray, S. Finn, 2017, Oncotarget.

A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC).

M. Tsao, F. Shepherd, A. Azad, 2014, Lung cancer.

Cancer patients’ acceptance, understanding, and willingness-to-pay for pharmacogenomic testing

Wei Xu, Xin Qiu, A. Azad, 2014, Pharmacogenetics and genomics.

Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project

K. Nackaerts, U. Dafni, K. Syrigos, 2022, Modern Pathology.

Cancer patient acceptance, understanding, and willingness to pay for pharmacogenetic testing (PGT).

A. Azad, A. Issa, Geoffrey Liu, 2012 .

Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer.

S. Finn, S. Cuffe, K. Gately, 2019, Pharmacology & therapeutics.

Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers

J. Jett, F. Shepherd, H. Roberts, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma.

K. O'Byrne, S. Gray, S. Finn, 2016, International journal of oncology.

Development and characterisation of a panel of phosphatidylinositide 3-kinase – mammalian target of rapamycin inhibitor resistant lung cancer cell lines

K. O'Byrne, S. Maher, P. Dowling, 2018, Scientific Reports.

High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer.

F. Feuerhake, K. O'Byrne, E. Kay, 2014, Clinical lung cancer.

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.

A. Tafreshi, M. Pietanza, M. O'Brien, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Germline genetic variation, cancer outcome, and pharmacogenetics.

D. Christiani, Geoffrey Liu, R. Hung, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.

Bingshu E. Chen, L. Seymour, M. Tsao, 2016, Cancer epidemiology.

When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?

H. Pass, C. Goparaju, K. O'Byrne, 2019, Frontiers in Endocrinology.

Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma.

K. O'Byrne, S. Gray, S. Finn, 2017, International journal of oncology.

Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma.

K. O'Byrne, S. Gray, S. Finn, 2017, International journal of oncology.

Adjuvant chemotherapy for non-small-cell lung cancer in the elderly: a population-based study in Ontario, Canada.

F. Shepherd, W. Mackillop, G. Darling, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting the phosphatidylinosital 3-kinase, Akt, and mammalian target of rapamycin pathway in non-small cell lung cancer.

N. Leighl, S. Cuffe, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024

A. Tafreshi, M. O'Brien, J. Brahmer, 2017 .

The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?

M. Joerger, A. Byrne, S. Gray, 2016, Expert opinion on therapeutic targets.

LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%

A. Tafreshi, J. Riess, M. Pietanza, 2020 .

Acute kidney Injury due to Alectinib, an Anaplastic Lymphoma Kinase inhibitor

S. Cuffe, B. Doyle, B. Griffin, 2021 .

A. Tafreshi, M. O'Brien, J. Brahmer, 2017, The Lancet. Oncology.

1595P Acceptance of COVID-19 vaccination among cancer patients in an Irish cancer centre

W. Mullally, K. Cadoo, D. Gallagher, 2021, Annals of Oncology.

Second-hand smoke as a predictor of smoking cessation among lung cancer survivors.

F. Shepherd, Geoffrey Liu, W. Xu, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevalence of Insomnia in an Oncology Patient Population: An Irish Tertiary Referral Center Experience.

M. O’Donnell, S. Collier, A. O’Dwyer, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastroesophageal junction cancer (mGEJC): Subgroup analysis from TAGS.

G. Beretta, J. Tabernero, M. Alsina, 2019, Journal of Clinical Oncology.

BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial

Bingshu E. Chen, D. Cescon, L. Seymour, 2016, Clinical Cancer Research.

Vaping and lung cancer - A review of current data and recommendations.

A. Baird, S. Finn, S. Cuffe, 2021, Lung cancer.

A randomised open-label phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC - the ETOP and EORTC SPLENDOUR trial.

N. Reinmuth, U. Dafni, R. Stahel, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

OA 17.06 Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50%

A. Tafreshi, M. Pietanza, M. O'Brien, 2017 .

Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial.

U. Dafni, E. Smit, A. Dingemans, 2022, Lung cancer.

Brief Report on the Detection of the EGFR T790M Mutation in Exhaled Breath Condensate from Lung Cancer Patients

B. Hennessy, A. Sartori, O. Breathnach, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial

R. Stahel, B. Cho, M. Provencio, 2021, Annals of Oncology.

KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%

Y. Shentu, A. Tafreshi, M. O'Brien, 2016 .

Modern oncological and operative outcomes in oesophageal cancer: the St. James’s hospital experience

M. Lowery, J. Reynolds, C. Ryan, 2020, Irish Journal of Medical Science (1971 -).

Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC

K. O'Byrne, C. Blanco-Aparicio, S. Finn, 2021, Cancers.

When your Best is not Good Enough

J. Knox, S. Cuffe, A. Horgan, 2011, Journal of Cancer Education.

Clinical utility of portable electrophysiology to measure fatigue in treatment-naïve non-small cell lung cancer

R. Reilly, D. Walsh, S. Cuffe, 2018, Supportive Care in Cancer.

Patient knowledge, personal experience, and impact of the first wave of the COVD-19 pandemic in an Irish oncology cohort

M. Lowery, F. Kelleher, C. Grant, 2022, Irish Journal of Medical Science (1971 -).

Inhibition and exploitation of aldehyde dehydrogenase 1 (ALDH1) as a cancer stem cell marker in cisplatin resistant NSCLC: 75P

K. O'Byrne, S. Gray, S. Finn, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

75P Inhibition and exploitation of aldehyde dehydrogenase 1 (ALDH1) as a cancer stem cell marker in cisplatin resistant NSCLC

K. O'Byrne, R. Rosell, S. Pilotto, 2016 .

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?

S. Gray, S. Finn, S. Cuffe, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial

Bingshu E. Chen, D. Cescon, L. Seymour, 2016, Clinical Cancer Research.

Development and characterisation of a panel of phosphatidylinositide 3-kinase – mammalian target of rapamycin inhibitor resistant lung cancer cell lines

K. O'Byrne, S. Maher, P. Dowling, 2018, Scientific Reports.

Second-hand smoke as a predictor of smoking cessation among lung cancer survivors.

F. Shepherd, Geoffrey Liu, W. Xu, 2014, Journal of Clinical Oncology.

Adoption of adjuvant chemotherapy (ACT) for non-small cell lung cancer (NSCLC) in the elderly: A population-based outcomes study.

F. Shepherd, W. Mackillop, G. Darling, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial

M. Lowery, G. Piessen, R. Turkington, 2023, The lancet. Gastroenterology & hepatology.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?

S. Gray, S. Finn, S. Cuffe, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Feasibility Randomised Control Trial of OptiMal: A Self-Management Intervention for Cancer Survivors

S. Cuffe, L. Boland, Deirdre Connolly, 2023, Current oncology.